Literature DB >> 28620889

Levels of MicroRNA Heterogeneity in Cancer Biology.

Nina Petrovic1,2, Sercan Ergün3, Esma R Isenovic4,5.   

Abstract

MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression, involved in the silencing of messenger RNA (mRNA) translation. The importance of miRNA signatures in disease screening, prognosis, and progression of different tumor types and subtypes is increasing. miRNA expression levels change depending on numerous factors. In this review, we are describing the circumstances under which miRNA levels can change, these are named 'levels' of heterogeneity of miRNAs. miRNAs can have oncogenic, tumor suppressive, or both roles depending on tumor type and target mRNA whose translation they silence. The expression levels of a single miRNA may vary across different cancer types and subtypes, indicating that a miRNA signature may be tissue specific. miRNA levels of expression also vary during disease formation and propagation, indicating the presence of a time profile for their expression. The complexity of the miRNA-mRNA interference network mirrors different genetic and epigenetic changes that influence miRNA and mRNA availability to each other, and hence, their binding ability. The potential role of miRNAs as biomarkers is two-fold; first, for monitoring of the phases of cancer pathogenesis, and second, to characterize the particular type/subtype of cancer. It is important that a particular miRNA should be characterized by examining as many types and subtypes of cancers as are available, as well as being extracted from different types of samples, in order to obtain a complete picture of its behavior and importance in the disease pathology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28620889     DOI: 10.1007/s40291-017-0285-9

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  90 in total

Review 1.  Functional relevance of miRNA sequences in human disease.

Authors:  Mihir K Bhayani; George A Calin; Stephen Y Lai
Journal:  Mutat Res       Date:  2011-11-06       Impact factor: 2.433

2.  Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesis.

Authors:  Young-Kook Kim; Boseon Kim; V Narry Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

3.  Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.

Authors:  Nina Petrovic; Radoslav Davidovic; Snezana Jovanovic-Cupic; Milena Krajnovic; Silvana Lukic; Milan Petrovic; Jelena Roganovic
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

4.  MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.

Authors:  Yoon Jin Cha; Joo Hyun Lee; Hyun Ho Han; Baek Gil Kim; Suki Kang; Young Deuk Choi; Nam Hoon Cho
Journal:  Prostate       Date:  2016-03-28       Impact factor: 4.104

5.  Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis.

Authors:  Jie Xiang; Ji Wu
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

6.  Targeting miR-21 for the therapy of pancreatic cancer.

Authors:  Flavie Sicard; Marion Gayral; Hubert Lulka; Louis Buscail; Pierre Cordelier
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

7.  Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines.

Authors:  Sercan Ergun; Kaifee Arman; Ebru Temiz; Ibrahim Bozgeyik; Önder Yumrutaş; Muhammad Safdar; Hasan Dağlı; Ahmet Arslan; Serdar Oztuzcu
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

8.  miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner.

Authors:  Nora Bandi; Erik Vassella
Journal:  Mol Cancer       Date:  2011-05-16       Impact factor: 27.401

9.  Suppression of miR-221 inhibits glioma cells proliferation and invasion via targeting SEMA3B.

Authors:  Guilan Cai; Shanshan Qiao; Kui Chen
Journal:  Biol Res       Date:  2015-07-22       Impact factor: 5.612

10.  A new polymorphism biomarker rs629367 associated with increased risk and poor survival of gastric cancer in chinese by up-regulated miRNA-let-7a expression.

Authors:  Qian Xu; Qiguan Dong; Caiyun He; Wenjing Liu; Liping Sun; Jingwei Liu; Chengzhong Xing; Xiaohang Li; Bengang Wang; Yuan Yuan
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

View more
  13 in total

Review 1.  miRNAs as Potential Treatment Targets and Treatment Options in Cancer.

Authors:  Nina Petrovic; Sercan Ergun
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

2.  Acquisition of Invasiveness by Breast Adenocarcinoma Cells Engages Established Hallmarks and Novel Regulatory Mechanisms.

Authors:  Hanaa Mousa; Mahmoud Elgamal; Reham Ghazal Marei; Nazariy Souchelnytskyi; Kah-Wai Lin; Serhiy Souchelnytskyi
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

3.  miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes.

Authors:  Giuliana Ventriglia; Francesca Mancarella; Guido Sebastiani; Dana P Cook; Roberto Mallone; Chantal Mathieu; Conny Gysemans; Francesco Dotta
Journal:  Diabetologia       Date:  2019-10-28       Impact factor: 10.122

4.  LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer.

Authors:  Honggang Sun; Liqin He; Lan Ma; Tao Lu; Jianguo Wei; Kejie Xie; Xingmu Wang
Journal:  Oncotarget       Date:  2017-11-30

5.  Characterization of circulating miRNA signature in water buffaloes (Bubalus bubalis) during Brucella abortus infection and evaluation as potential biomarkers for non-invasive diagnosis in vaginal fluid.

Authors:  Cristina Lecchi; Carlotta Catozzi; Valentina Zamarian; Gaia Poggi; Giorgia Borriello; Alessandra Martucciello; Domenico Vecchio; Esterina DeCarlo; Giorgio Galiero; Fabrizio Ceciliani
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

Review 6.  MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside.

Authors:  Margherita Ratti; Andrea Lampis; Michele Ghidini; Massimiliano Salati; Milko B Mirchev; Nicola Valeri; Jens C Hahne
Journal:  Target Oncol       Date:  2020-06       Impact factor: 4.493

Review 7.  Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Authors:  Nina Petrović; Irina Nakashidze; Milica Nedeljković
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-21       Impact factor: 2.673

8.  Clinical significance of microRNA-449a in hepatocellular carcinoma with microarray data mining together with initial bioinformatics analysis.

Authors:  Xia Yang; Han-Lin Wang; Hai-Wei Liang; Liang Liang; Dong-Yue Wen; Rui Zhang; Gang Chen; Dan-Ming Wei
Journal:  Exp Ther Med       Date:  2018-02-05       Impact factor: 2.447

Review 9.  Research progress on the relationship between zinc deficiency, related microRNAs, and esophageal carcinoma.

Authors:  Cong-Min Liu; Di Liang; Jing Jin; Dao-Juan Li; Ya-Chen Zhang; Zhao-Yu Gao; Yu-Tong He
Journal:  Thorac Cancer       Date:  2017-09-11       Impact factor: 3.500

10.  Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer.

Authors:  Nan Wang; Huihui Guo; Zhaohuo Dong; Qiuqiang Chen; Xilin Zhang; Weiyun Shen; Ying Bao; Xiang Wang
Journal:  Cancer Manag Res       Date:  2018-09-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.